Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers.

MLA

Tokat, Ünal Metin, et al. “Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers.” Current Oncology, vol. 31, no. 10, Oct. 2024, pp. 5838–49. EBSCOhost, https://doi.org/10.3390/curroncol31100434.

APA

Tokat, Ü. M., Adibi, A., Aydın, E., Özgü, E., Bilgiç, Ş. N., Tutar, O., Özbek Doğançay, M., Demiray, İ., & Demiray, M. (2024). Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers. Current Oncology, 31(10), 5838–5849. https://doi.org/10.3390/curroncol31100434

Chicago

Tokat, Ünal Metin, Ashkan Adibi, Esranur Aydın, Eylül Özgü, Şevval Nur Bilgiç, Onur Tutar, Merve Özbek Doğançay, İrem Demiray, and Mutlu Demiray. 2024. “Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers.” Current Oncology 31 (10): 5838–49. doi:10.3390/curroncol31100434.